Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study.
Marco Di NicolaMichael AdairA RieckmannMichael Cronquist ChristensenPublished in: Journal of psychopharmacology (Oxford, England) (2024)
Consistent with previous clinical studies of vortioxetine, this study supports the effectiveness and safety of vortioxetine in treating elderly patients with MDD in a real-world setting over a 6-month period. Patients showed clinically relevant and sustained improvements in psychosocial functioning, depressive symptoms, and cognitive function after receiving vortioxetine, which was generally well tolerated. Main study limitations include the open-label study design and lack of a placebo or comparator group.
Keyphrases
- major depressive disorder
- bipolar disorder
- depressive symptoms
- open label
- randomized controlled trial
- clinical practice
- clinical trial
- systematic review
- end stage renal disease
- chronic kidney disease
- squamous cell carcinoma
- mental health
- physical activity
- middle aged
- prognostic factors
- study protocol
- phase iii
- rectal cancer
- social support
- sleep quality
- patient reported